Sarah Lazzaro

555 total citations
15 papers, 353 citations indexed

About

Sarah Lazzaro is a scholar working on Oncology, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Sarah Lazzaro has authored 15 papers receiving a total of 353 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Pharmacology and 6 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Sarah Lazzaro's work include Drug Transport and Resistance Mechanisms (12 papers), Pharmacogenetics and Drug Metabolism (7 papers) and Pharmacological Effects and Toxicity Studies (6 papers). Sarah Lazzaro is often cited by papers focused on Drug Transport and Resistance Mechanisms (12 papers), Pharmacogenetics and Drug Metabolism (7 papers) and Pharmacological Effects and Toxicity Studies (6 papers). Sarah Lazzaro collaborates with scholars based in United States, China and Saudi Arabia. Sarah Lazzaro's co-authors include Manthena V. S. Varma, Chester Costales, Emi Kimoto, Mark A. West, Yi‐An Bi, A. David Rodrigues, Larry M. Tremaine, Shinji Yamazaki, Renato J. Scialis and Sumathy Mathialagan and has published in prestigious journals such as Journal of Pharmacology and Experimental Therapeutics, Pharmaceutical Research and Journal of Pharmaceutical Sciences.

In The Last Decade

Sarah Lazzaro

14 papers receiving 345 citations

Peers

Countries citing papers authored by Sarah Lazzaro

Since Specialization

Citations

This map shows the geographic impact of Sarah Lazzaro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Lazzaro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Lazzaro more than expected).

Fields of papers citing papers by Sarah Lazzaro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Lazzaro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Lazzaro. The network helps show where Sarah Lazzaro may publish in the future.

Co-authorship network of co-authors of Sarah Lazzaro

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Lazzaro. A scholar is included among the top collaborators of Sarah Lazzaro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Lazzaro. Sarah Lazzaro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Significance of gut breast cancer resistance protein versus organic anion transporting polypeptide 2B1 inhibition on rosuvastatin clinical drug-drug interactions 2025 ·Drug Metabolism and Disposition ·Mark A. West, Sarah Lazzaro, (unknown), Chester Costales, Sook Wah Yee, Manthena V. S. Varma	0
2	Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter Activity 2023 ·Pharmaceutical Research ·(unknown), Anna Plotka, (unknown), Julia Kaplan, (unknown), (unknown), Vivek S. Purohit, Martin E. Dowty, Robert Wołk, Manoli Vourvahis, Amanda King‐Ahmad, Sumathy Mathialagan, Mark A. West, Sarah Lazzaro, Sangwoo Ryu, A. David Rodrigues	3
3	Attempting to Unmask the Inhibition of Sulfotransferase 1E1 in 17α‐Ethinyl Estradiol Drug Interactions 2023 ·The Journal of Clinical Pharmacology ·David Rodrigues, Mark Niosi, Heather Eng, Christopher Healy, Sarah Lazzaro, (unknown), Matthew A. Cerny	2
4	Translatability of in vitro Inhibition Potency to in vivo P-Glycoprotein Mediated Drug Interaction Risk 2023 ·Journal of Pharmaceutical Sciences ·Sarah Lazzaro, Mark A. West, (unknown), Bo Feng, Manthena V. S. Varma, A. David Rodrigues, (unknown), (unknown), (unknown), Zsuzsanna Gáborik, Chester Costales	5
5	Quantitative prediction of breast cancer resistant protein mediated drug‐drug interactions using physiologically‐based pharmacokinetic modeling 2021 ·CPT Pharmacometrics & Systems Pharmacology ·Chester Costales, Jian Lin, Emi Kimoto, Shinji Yamazaki, J Gosset, A. David Rodrigues, Sarah Lazzaro, Mark A. West, (unknown), Manthena V. S. Varma	39
6	Evaluation of Nigerian Medicinal Plants Extract on Human P-glycoprotein andCytochrome P450 Enzyme Induction: Implications for Herb-drug Interaction 2021 ·Current Drug Metabolism ·(unknown), Emily Marques, Wei Wei, Sarah Lazzaro, Nathaniel Johnson, Manthena V. S. Varma, Angela L. Slitt	3
7	Saudiarabicains A-E, bioactive 19-acetoxyingol diterpenoids from Euphorbia saudiarabica 2020 ·Tetrahedron Letters ·Abdullatif Bin Muhsinah, Alfarius Eko Nugroho, Huifang Li, Sarah Lazzaro, Nicholas A. DaSilva, Dongli Li, Hang Ma, Abdulrhman Alsayari, Hiroshi Morita, Yongqiang Liu, Navindra P. Seeram	5
8	Identification of Glycochenodeoxycholate 3‐O‐Glucuronide and Glycodeoxycholate 3‐O‐Glucuronide as Highly Sensitive and Specific OATP1B1 Biomarkers 2020 ·Clinical Pharmacology & Therapeutics ·Mikko Neuvonen, (unknown), Aleksi Tornio, Brian Rago, Mark A. West, Sarah Lazzaro, Sumathy Mathialagan, Manthena V. S. Varma, Matthew A. Cerny, Chester Costales, Ragu Ramanathan, A. David Rodrigues, Mikko Niemi	35
9	Quantitative Contribution of Six Major Transporters to the Hepatic Uptake of Drugs: “SLC-Phenotyping” Using Primary Human Hepatocytes 2019 ·Journal of Pharmacology and Experimental Therapeutics ·Yi‐An Bi, Chester Costales, Sumathy Mathialagan, Mark A. West, (unknown), Sarah Lazzaro, Laurie Tylaska, Renato J. Scialis, Hui Zhang, John P. Umland, Emi Kimoto, David A. Tess, Bo Feng, Larry M. Tremaine, Manthena V. S. Varma, A. David Rodrigues	66
10	Physiologically‐Based Pharmacokinetic Modeling Approach to Predict Rifampin‐Mediated Intestinal P‐Glycoprotein Induction 2019 ·CPT Pharmacometrics & Systems Pharmacology ·Shinji Yamazaki, Chester Costales, Sarah Lazzaro, (unknown), Emi Kimoto, Manthena V. S. Varma	43
11	Moving beyond Binary Predictions of Human Drug-Induced Liver Injury (DILI) toward Contrasting Relative Risk Potential 2019 ·Chemical Research in Toxicology ·Michael D. Aleo, Falgun Shah, Scott W. Allen, Hugh A. Barton, Chester Costales, Sarah Lazzaro, Louis Leung, (unknown), R. Scott Obach, A. David Rodrigues, Yvonne Will	43
12	Clopidogrel as a Perpetrator of Drug–Drug Interactions: A Challenge for Quantitative Predictions? 2019 ·Clinical Pharmacology & Therapeutics ·Manthena V. S. Varma, Yi‐An Bi, Sarah Lazzaro, Mark A. West	12
13	Simultaneous Assessment of Transporter-Mediated Drug–Drug Interactions Using a Probe Drug Cocktail in Cynomolgus Monkey 2018 ·Drug Metabolism and Disposition ·Rachel E. Kosa, Sarah Lazzaro, Yi‐An Bi, (unknown), (unknown), Sweta Modi, Chester Costales, A. David Rodrigues, Larry M. Tremaine, Manthena V. S. Varma	35
14	Reliable Rate Measurements for Active and Passive Hepatic Uptake Using Plated Human Hepatocytes 2017 ·The AAPS Journal ·Yi‐An Bi, Renato J. Scialis, Sarah Lazzaro, Sumathy Mathialagan, Emi Kimoto, (unknown), Hui Zhang, Anna Vildhede, Chester Costales, A. David Rodrigues, Larry M. Tremaine, Manthena V. S. Varma	39
15	The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide–Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy 2016 ·Drug Metabolism and Disposition ·Heather Eng, Renato J. Scialis, Charles J. Rotter, Jun Lin, Sarah Lazzaro, Manthena V. S. Varma, Li Di, Bo Feng, Mark A. West, Amit S. Kalgutkar	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact